TLSA Stock Forecast: Tiziana Life Sciences Ltd. (Bermuda) Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.68
−16.59% on the day

The median 12-month analyst price target for Tiziana Life Sciences Ltd. (Bermuda) is $7.85. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$82.7M
Ticker Nerd rank
25/ 100
Median analyst target
$7.85
Analysts covering
2
Total return, dividends reinvested
1W
+10.8%
1M
−33.1%
YTD
−54.7%
1Y
−60.0%
From 52W high
−62.9%
From 52W low
+18.5%
$0.57
$1.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tiziana Life Sciences Ltd. (Bermuda) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
25/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Volatility
72
Value
52
Revisions
39
Growth
21
Momentum
18
Issuance
16
Quality
10

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TLSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26TLSAHigh $8.83Median $7.85Low $6.87

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$6.87
Low
$7.85
Median
$8.83
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026BTIGReiteratesBuy$7.00
3 Sept 2026BTIGInitiatesBuy$7.00
6 Sept 2022ThinkEquityInitiatesBuy—
13 June 2022ThinkEquityInitiatesBuy—
12 Apr 2021Zacks Investment ResearchInitiatesNot Rated—
21 Sept 2020HC Wainwright & Co.MaintainsBuy$25 → $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TLSA.

Market Radar

This page is one stock. Monday covers all of them.

TLSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TLSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Tiziana Life Sciences Ltd. (Bermuda) returned −60.0% against +9.2% for the S&P 500, dividends included.

TLSA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TLSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
14.4×

Cheaper than 5% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−780.6%

Higher than 2% of US stocks

Return on assets
−103.2%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tiziana Life Sciences Ltd. (Bermuda) has a market value of $82.7M and an enterprise value of $80.7M.

  • Shares outstanding: 120.5M.

  • Tiziana Life Sciences Ltd. (Bermuda) employs 10 people.

market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

TLSA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TLSATiziana Life Sciences Ltd. (Bermuda)$82.7M25
UNCYUnicycive Therapeutics, Inc.$104.2M36
CBUSCibus, Inc.$104.4M27
FHTXFoghorn Therapeutics, Inc.$104.9M56
ICCCImmuCell Corp.$102.3M94
LENZLENZ Therapeutics, Inc.$100.9M22
GNLXGenelux Corp.$107.7M14

Take a look at TLSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tiziana Life Sciences Ltd. (Bermuda) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TLSA

What is the TLSA stock price forecast for 2026-2027?

The median 12-month analyst price target for Tiziana Life Sciences Ltd. (Bermuda) is $7.85, with estimates ranging from $6.87 to $8.83. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSA stock a buy right now?

Of the 2 analysts covering Tiziana Life Sciences Ltd. (Bermuda), 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 25 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSA?

As at 18 Nov 2026, Tiziana Life Sciences Ltd. (Bermuda) ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will TLSA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $7.85, and Ticker Nerd's factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 25 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSA stock forecast for 2030?

No analyst covering Tiziana Life Sciences Ltd. (Bermuda) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.87 to $8.83 over the next 12 months.

How has TLSA stock performed over the past year?

Tiziana Life Sciences Ltd. (Bermuda) returned -60.0% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tiziana Life Sciences Ltd. (Bermuda) do?

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders.

Company

About Tiziana Life Sciences Ltd. (Bermuda).

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.

CEO Dr. Ivor R. Elrifi Ph.D. · 10 employees · United Kingdom · https://www.tizianalifesciences.com